Peroxisome Proliferator-Activated Receptor gamma (PPARγ) antagonists have demonstrated therapeutic efficacy in NASH, while Peroxisome Proliferator-Activated Receptor Delta (PPARδ) activation improved fatty acid oxidation and inhibited hepatic liposynthesis and gluconeogenesis (27). The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.